These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, Bousquet J. Br J Clin Pharmacol; 2012 Jul; 74(1):125-33. PubMed ID: 22356350 [Abstract] [Full Text] [Related]
8. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, Hadley J, Lieberman P, Hampel FC, Mullol J, Munzel U, Price D, Scadding G, Virchow JC, Wahn U, Murray R, Bousquet J. Int Arch Allergy Immunol; 2013 Jul; 161(4):369-77. PubMed ID: 23652808 [Abstract] [Full Text] [Related]
9. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, Bhatia S. J Allergy Clin Immunol Pract; 2014 Jul; 2(2):179-85. PubMed ID: 24607046 [Abstract] [Full Text] [Related]
13. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Carr WW, Ratner P, Munzel U, Murray R, Price D, Canonica GW, Mullol J, Virchow JC, Lieberman P, Meltzer E, Bachert C. Allergy Asthma Proc; 2012 Jul; 33(6):450-8. PubMed ID: 23127291 [Abstract] [Full Text] [Related]
14. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Ilyina NI, Edin AS, Astafieva NG, Lopatin AS, Sidorenko IV, Ukhanova OP, Khanova FM. Int Arch Allergy Immunol; 2019 Jul; 178(3):255-263. PubMed ID: 30677766 [Abstract] [Full Text] [Related]
15. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, Kasran A, Talavera K, Wouters MM, Ceuppens JL, Seys SF, Hellings PW. Allergy; 2018 May; 73(5):1084-1093. PubMed ID: 29121401 [Abstract] [Full Text] [Related]
16. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. Prenner BM. J Asthma Allergy; 2016 May; 9():135-43. PubMed ID: 27468241 [Abstract] [Full Text] [Related]